This paper is only available as a PDF. To read, Please Download here.
Abstract
The transdermal and oral administration of estrogens for one year were compared with
respect to the effects on lipid metabolism. Eighty-one postmenopausal women (1.5-3
years after menopause) were randomly divided into three groups. The first two groups
received sequential estrogen treatment with either transdermal estradiol (Estraderm
TTS, Ciba Geigy; 50 μg/day; 24 women) or 0.625 mg/day conjugated estrogens (Premarin,
Wyeth; 20 subjects), respectively. In both groups medroxyprogesterone (10 mg/day per
os) was added for 12 days of each cycle. Thirty-five subjects served as control group
without therapy. No significant changes in the lipid profile was observed in control
subjects after 1 year of follow-up. Serum triglycerides decreased significantly (-10.9
± 26% S.D.; P < 0.05) in transdermal treated women, whereas it slightly rose in oral estrogen group.
Comparable significant decreases in total and low density lipoprotein (LDL) cholesterol
(mean range -6.5/-18.0%) were observed in women on estrogen replacement therapy. High
density lipoprotein (HDL) cholesterol significantly diminished in transdermal estradiol
group, but it rose slightly in the oral estrogen group. Thus the fraction of HDL cholesterol
over LDL cholesterol did not change in the transdermal group whereas it significantly
rose in subjects treated with oral estrogens. It remains to be established to what
extent these differences on lipid metabolism are relevant for the prevention of cardiovascular
diseases.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to MaturitasAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Menopause and coronary heart disease.in: The Framingham Study. Ann Intern Med. 89. 1978: 157-161
- Some atherogenic concomitants of menopause.in: The Framingham Study. Am J Epidemiol. 103. 1976: 304-311
- Menopause and risk factors for coronary heart disease.N Engl J Med. 1989; 321: 641-646
- Cardiovascular mortality and noncontraceptive use of estrogen in women.Circulation. 1987; 75: 1102-1109
- Comparison of lipid and androgen levels after conjugated estrogen or depo-medroxyprogesterone acetate treatment in postmenopausal women.Obstet Gynecol. 1985; 66: 217-218
- A prospective one-year study of estrogen and progestin in postmenopausal women: effects on clined symptoms and lipoprotein lipids.Obstet Gynecol. 1989; 73: 759-766
- The effects of conjugated equine oestrogens with and without a cyclical progestogen on lipoproteins and HDL subfractions in postmenopausal women.Acta Endocrinol. 1986; 113: 123-127
- Differential lipemic and hormonal responses to oral and parenteral 17β-estradiol in postmenopausal women.Am J Obstet Gynecol. 1983; 147: 77-81
- Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins.N Engl J Med. 1991; 325: 1196-1204
- Long-term effects of percutaneous estrogens and oral progesterone on serum lipoproteins in postmenopausal women.Am J Obstet Gynecol. 1987; 156: 66-71
- Biologic effects of transdermal estradiol.N Engl J Med. 1986; 314: 1615-1620
- A randomized comparison of nonoral estradiol delivery in postmenopausal women.Am J Obstet Gynecol. 1988; 159: 1540-1546
- Altered plasma lipid and lipoprotein levels associated with oral contraceptives and estrogen use.Lancet. 1979; 2: 111-115
- Oestrogens, gonadotrophins and SHBG during oral and cutaneous administration of oestradiol-17β to menopausal women.Acta Endocrinol. 1982; 101: 592-596
- Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.Clin Chem. 1972; 18: 499-502
- Effect of bilateral ovariectomy on coronary-artery disease and serum-lipid levels.Lancet. 1959; 2: 690-694
- Estrogen replacement therapy and protection from acute myocardial infarction.Am J Obstet Gynecol. 1988; 159: 312-317
- Risk factors and noncontraceptive estrogen use in women with and without coronary disease.Am Heart J. 1989; 117: 1209-1214
- Estrogen replacement and coronary artery disease.Arch Intern Med. 1990; 150: 2557-2562
- Postmenopausal estrogen therapy and cardiovascular disease.N Engl J Med. 1991; 325: 756-762
- Pulsatility index in internal carotid artery in relation to transdermal oestradiol and time since menopause.Lancet. 1991; 2: 839-842
- The lipid research clinics coronary primary prevention trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering.Jama. 1984; 251: 365-374
- Natural oestrogen as an effective treatment for type II hyperlipoproteinaemia in postmenopausal women.Lancet. 1978; 2: 490-492
- Efficacy of transdermal estradiol.Am J Obstet Gynecol. 1987; 156: 1326-1331
- Treatment of postmenopausal osteoporosis with transdermal estrogen.Ann Intern Med. 1992; 117: 1-9
- Clinical and lipid metabolic effects of unapposed estrogen and two estrogen-progestagen regimens in post-menopausal women.Maturitas. 1987; 9: 69-79
- Ovarian function and lipid/lipoprotein levels: results from the Lipid Research Clinics Program.Am J Epidemiol. 1984; 120: 489
- Influence of menopause on serum lipids and lipoproteins.Maturitas. 1990; 12: 321-331
Article info
Publication history
Accepted:
January 8,
1993
Received in revised form:
January 8,
1993
Received:
September 22,
1992
Identification
Copyright
© 1993 Published by Elsevier Inc.
